DAEJEON, South Korea – Alteogen Inc. (KOSDAQ: 196170) will present at the APAC Track of the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 11:30 a.m. PT.

About Alteogen Inc.

Alteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP™-fusion and NexMab™ platform technology, respectively. It also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme™ technology, which enables the large volume subcutaneous administration of drugs that are typically administered as an IV infusion. The company was founded in 2008 and listed on KOSDAQ (196170.KQ).

For further information, please contact:

Investor contact:

ir@alteogen.com